A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials

J Cancer Res Clin Oncol. 2023 Nov;149(14):12897-12902. doi: 10.1007/s00432-023-05137-8. Epub 2023 Jul 19.

¹ Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany.
² Institute of Biometry and Epidemiology, University Hospital of Würzburg, Würzburg, Germany.
³ Department of Hematology, Oncology and Palliative Medicine, Ernst Von Bergmann Hospital, Potsdam, Germany.
⁴ Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany.
⁵ Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080, Würzburg, Germany. Rasche_L@ukw.de.

^# Contributed equally.

No abstract available

Keywords: Endpoint measure; Lenalidomide maintenance therapy; Multiple myeloma; Patient involvement; Progression-free survival; Quality of life.

Grants and funding